�y��vlog

Luo, who initiated this research to improve existing therapies for AML, also treated animal models of leukemia with cytarabine alone and with eganelisib plus cytarabine.

The team found that those treated with a combination of eganelisib and cytarabine survived longer than those treated with cytarabine alone, regardless of the leukemia's sensitivity to PI3Kgamma inhibition alone.

Luo also discovered that leukemia cells that survive standard treatment with cytarabine tend to be more dependent on PI3Kgamma than they were prior to treatment.

These surviving leukemia cells -- which are the cause of AML relapse -- could be vulnerable to combination therapy with eganelisib and cytarabine.

He said cancer drugs like Filgrastim and Cytarabine, as well as some antibiotics, were in short supply.